GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Acquired by Boston Common Asset Management LLC

Boston Common Asset Management LLC lifted its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 47,655 shares of the company’s stock after acquiring an additional 750 shares during the period. Boston Common Asset Management LLC’s holdings in GE HealthCare Technologies were worth $3,726,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in GEHC. Mercer Global Advisors Inc. ADV boosted its holdings in shares of GE HealthCare Technologies by 15.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 24,326 shares of the company’s stock worth $1,931,000 after purchasing an additional 3,303 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of GE HealthCare Technologies by 16.8% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,771 shares of the company’s stock worth $528,000 after purchasing an additional 976 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of GE HealthCare Technologies by 2.6% during the second quarter. Amalgamated Bank now owns 85,418 shares of the company’s stock worth $6,656,000 after purchasing an additional 2,188 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of GE HealthCare Technologies by 10.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,684 shares of the company’s stock worth $2,391,000 after purchasing an additional 3,020 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in GE HealthCare Technologies by 0.3% in the second quarter. Blair William & Co. IL now owns 110,258 shares of the company’s stock valued at $8,591,000 after acquiring an additional 294 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Trading Down 0.3 %

NASDAQ:GEHC opened at $84.74 on Friday. The business’s 50-day moving average is $81.98 and its two-hundred day moving average is $84.33. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. GE HealthCare Technologies Inc. has a 12 month low of $71.31 and a 12 month high of $94.55. The firm has a market capitalization of $38.72 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 2.80 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The business had revenue of $4.86 billion for the quarter, compared to analyst estimates of $4.87 billion. During the same period in the previous year, the company earned $0.99 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. Research analysts predict that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Tuesday, January 14th. GE HealthCare Technologies’s payout ratio is presently 3.30%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GEHC. Stifel Nicolaus lifted their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a report on Monday, September 30th. Wells Fargo & Company lifted their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. UBS Group cut GE HealthCare Technologies from a “neutral” rating to a “sell” rating and reduced their target price for the company from $84.00 to $74.00 in a report on Thursday, September 26th. Finally, Evercore ISI lifted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.00.

Insider Transactions at GE HealthCare Technologies

In other news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.